Results 11 to 20 of about 10,075 (184)

Transcriptomic and miRNA Signatures of ChAdOx1 nCoV-19 Vaccine Response Using Machine Learning [PDF]

Life
Vaccination with ChAdOx1 nCoV-19 is an important countermeasure to fight the COVID-19 pandemic. This vaccine enhances human immunoprotection against SARS-CoV-2 by inducing an immune response against the SARS-CoV-2 S protein.
Jinting Lin, Qinglan Ma, Lei Chen, Wei Guo, Kaiyan Feng, Tao Huang, Yu-Dong Cai   +6 more
doaj   +3 more sources

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

Vaccines, 2021
It is unclear whether the ChAdOx1 nCov-19 vaccine can induce the development of anti-PF4 antibodies in vaccinated individuals who have not developed thrombosis.
Evangelos Terpos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, Vangelis Karalis, Efrosyni Merkouri, Despina Fotiou, Maria Gavriatopoulou, Panagiotis Malandrakis, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos   +10 more
doaj   +4 more sources

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine [PDF]

eLife, 2022
ChAdOx1 nCov-19 and Ad26.COV2.S are approved vaccines inducing protective immunity against SARS-CoV-2 infection in humans by expressing the Spike protein of SARS-CoV-2. We analyzed protein content and protein composition of ChAdOx1 nCov-19 and Ad26.COV2.S by biochemical methods and by mass spectrometry.
Lea Krutzke, Reinhild Rösler, Ellen Allmendinger, Tatjana Engler, Sebastian Wiese, Stefan Kochanek   +5 more
core   +5 more sources

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults [PDF]

Scientific Reports
We assessed S-268019-b, a recombinant spike protein vaccine with a squalene-based adjuvant, for superiority in its immunogenicity over ChAdOx1 nCoV-19 vaccine among adults in Japan. In this multicenter, randomized, observer-blinded, phase 3 study, severe
Satoshi Iwata, Andrew J. Pollard, Yukio Tada, Shinya Omoto, Risa Y. Shibata, Kenji Igarashi, Takahiro Hasegawa, Mari Ariyasu, Takuhiro Sonoyama   +8 more
doaj   +3 more sources

Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines [PDF]

Haematologica, 2022
Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.
Stephan Michalik, Florian Siegerist, Raghavendra Palankar, Kati Franzke, Maximilian Schindler, Alexander Reder, Ulrike Seifert, Clemens Cammann, Jan Wesche, Leif Steil, Christian Hentschker, Manuela Gesell-Salazar, Emil Reisinger, Martin Beer, Nicole Endlich, Andreas Greinacher, Uwe Völker   +16 more
doaj   +2 more sources

COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19 [PDF]

Frontiers in Immunology, 2022
Evaluation of the safety and immunogenicity of new vaccine platforms is needed to increase public acceptance of coronavirus disease 2019 (COVID-19) vaccines.
Jung Yeon Heo, Yu Bin Seo, Eun Jin Kim, Jacob Lee, Young Rong Kim, Jin Gu Yoon, Ji Yun Noh, Ji Yun Noh, Ji Yun Noh, Hee Jin Cheong, Hee Jin Cheong, Hee Jin Cheong, Woo Joo Kim, Woo Joo Kim, Woo Joo Kim, Soo-Young Yoon, Ju-Yeon Choi, Young Jae Lee, Hye Won Lee, Sung Soon Kim, Byoungguk Kim, Joon Young Song, Joon Young Song, Joon Young Song   +23 more
doaj   +2 more sources

Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome [PDF]

Vaccines, 2022
Background: in this report, we describe the case of an 83-year-old woman vaccinated with ChadOx1 nCoV-19 who developed a so-called vaccine-induced thrombosis with thrombocytopenia syndrome and who did not develop any antibodies against the spike protein ...
Constant Gillot, Julien Favresse, Vincent Maloteau, Valérie Mathieux, Jean-Michel Dogné, François Mullier, Jonathan Douxfils   +6 more
doaj   +2 more sources

Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report [PDF]

Vaccines (Basel), 2023
Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than the mRNA vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce.
Parichat Uea-Areewongsa, Boonjing Siripaitoon, Nawamin Pinpathomrat, Siriporn Juthong, Jomkwan Ongarj, Porntip Intapiboon   +5 more
core   +2 more sources

Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine [PDF]

BMJ Case Reports, 2021
A 50-year-old Indian woman presented with acute dysphasia, left upper limb numbness and thrombocytopenia 12 days after receiving the ChAdOx1 nCoV-19 vaccine (AstraZeneca/Vaxzevria). MRI of the brain was unremarkable. Microangiopathic haemolytic anaemia with thrombocytopenia was noted on her peripheral blood film.
Hui Ping Lee, Veena Selvaratnam, Jay Suriar Rajasuriar   +2 more
openaire   +3 more sources

Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine [PDF]

The Lancet, 2021
As the COVID-19 pandemic evolves, public health authorities continue to make unprecedented decisions about the deployment of limited supplies of vaccines against COVID-19. One strategy to maximise the number of people immunised is to delay the second dose of vaccine, as was implemented in the UK and elsewhere, including for the Oxford–AstraZeneca
Rogawski McQuade, Elizabeth T, Breskin, Alexander   +1 more
openaire   +4 more sources